Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 ...
manilatimes41m
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical ...
manilatimes41m
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
Celerion to relocate Belfast clinical research operations to new £64m iREACH Health complex
THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million. Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung ...